Influenza, Human Clinical Trial
Official title:
Randomized, Double-blind, Comparative, Controlled Trial of Tolerability, Reactogenicity, Safety and Immunogenicity of Flu-M [Inactivated Split Influenza Vaccine] in Pregnant Women During the 2nd - 3rd Trimester
Verified date | July 2022 |
Source | St. Petersburg Research Institute of Vaccines and Sera |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Comparative study of tolerability, reactogenicity, safety and immunogenicity Flu-M [Inactivated Split Influenza Vaccine] vs. the Ultrix® vaccine for the prevention of influenza in pregnant women in the 2nd-3rd trimesters of pregnancy
Status | Completed |
Enrollment | 207 |
Est. completion date | July 26, 2021 |
Est. primary completion date | March 11, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 35 Years |
Eligibility | Inclusion Criteria: 1. Presence of signed Informed Consent of the female patient to participate in the trial 2. Healthy women aged 18 to 35 years in their 2nd and 3rd trimesters of pregnancy with gestational age of no more than 32 weeks 3. Singleton pregnancy progressing normally 4. No contraindications for vaccination 5. Pregnant women that are able to fulfill the requirements of the protocol (i.e., fill out the Self-Observation Diary, come to follow-up visits) 6. The investigator is given the opportunity to collect data about somatic, infectious, and allergic diseases within at least 3 months from vaccination (one or more calls from the clinical investigator or visits per month (as needed)) Exclusion Criteria: 1. Body temperature above 37°? 2. History of influenza or previous influenza vaccination during 6 months before the screening 3. History of allergic reactions to chicken protein 4. Allergic reactions to vaccine components or any previous vaccination 5. Gestational toxicosis 6. Any disorders of pregnancy 7. Thyroid disorders 8. Bronchial asthma 9. Clotting disorders 10. 1, 2 type diabetes mellitus 11. High risk of fetal chromosomal abnormalities (individual risk of at least 1/100) in the 1st trimester of pregnancy and/or the detection of fetal congenital anomalies / developmental defects in the 1st, 2nd, and 3rd trimesters of pregnancy 12. Strong reaction (temperature above 40 °C, hyperemia or edema more than 8 cm in diameter) or complications (collapse or shock-like condition) that developed within 48 hours from prior vaccination; convulsions accompanied or not accompanied by a fever due to any prior vaccination 13. Acute infectious or non-infectious diseases less than 4 weeks before the screening, exacerbation of chronic diseases (the vaccination can be carried out after recovery or in the period of remission) 14. Immunomodulatory therapy, including immune-enhancing, immunosuppressive therapy (corticosteroids, cytotoxic and radioactive drugs) in the 6 months preceding the trial 15. Any other contraindications against vaccination according to the investigator. 16. Leukemia, cancer or a positive reaction to HIV infection, hepatitis B and C, syphilis in the medical history 17. Volunteers who received immunoglobulin or blood products within the last three months before the trial 18. History of Guillain-Barré syndrome (acute polyneuropathy) 19. Autoimmune diseases 20. Any confirmed or suspected immunosuppressive or immunodeficiency condition 21. Respiratory, cardiovascular failure, impaired liver or kidney function. 22. Severe birth defects or serious chronic diseases, including any clinically significant chronic diseases of lungs, kidneys, cardiovascular, nervous system, psychiatric diseases or metabolic disorders, confirmed by medical history or objective examination 23. Vaccination with any vaccine less than 30 days before the screening or scheduled vaccination with any vaccine within 30 days from vaccination with the trial vaccines 24. The woman is/was a patient of a tuberculosis dispensary and/or narcological dispensary and/or neuropsychiatric dispensary 25. Chronic alcohol abuse and/or use of drugs in the past history 26. Smoking 27. Participation in another clinical trial during the last 3 months |
Country | Name | City | State |
---|---|---|---|
Russian Federation | Federal State Budgetary Educational Institution of Higher Education "Altai State Medical University" of the Ministry of Health of the Russian Federation | Barnaul | Altai Territory |
Russian Federation | Municipal Budgetary Institution "Central City Hospital No.7" | Ekaterinburg | |
Russian Federation | "Curator" Limited Liability Company | Saint Petersburg | |
Russian Federation | KOROLEV MEDICINE Limited Liability Company | Saint Petersburg | |
Russian Federation | Federal State Budgetary Institution "Siberian Federal Scientific and Clinical Center of Federal Medical and Biologic Agency" | Seversk | Tomsk Region |
Lead Sponsor | Collaborator |
---|---|
St. Petersburg Research Institute of Vaccines and Sera |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from Baseline Seroprotection rate at day 21 after vaccination | The percentage of vaccinees who have an antibody titer of more than 1:40 by Day 21 after vaccination.
Antibodies to influenza B, ? (H1N1), ? (H3N2) viruses Seroprotection rate = 70%. |
Days 0 (screening), 21 | |
Primary | Change from Baseline Seroconversion rate at day 21 after vaccination | The relative number of vaccinees, whose titer of hemagglutinin inhibiting antibodies has increased by more than 4 times vs. baseline among all immunoprotective persons.
Antibodies to influenza B, ? (H1N1), ? (H3N2) viruses Seroconversion rate = 40% |
Days 0 (screening), 21 | |
Primary | Change from Baseline Seroconversion factor at day 21 after vaccination | An increase in the geometric mean titers of hemagglutinin inhibiting antibodies on Day 21 vs. baseline, expressed in multiplicity of increase.
Antibodies to influenza B, ? (H1N1), ? (H3N2) viruses Seroconversion factor = 2.5 |
Days 0 (screening), 21 | |
Secondary | Incidence of AEs and SAEs associated with vaccination | The degree of intensity or severity of AE was evaluated on a 4-point scale:
0 - none (no symptoms) - mild (mild symptoms) - moderate (symptoms that disrupt normal daily activities to a certain extent) - severe (symptoms that disrupt normal daily activities) |
Day 1 (30 minutes, 3 and 5 hours after vaccination), days 2-21 | |
Secondary | Number of participants with abnormal changes in physical examination data | Physical examination includes examination of the general appearance, condition of the skin and mucous membranes, neck (including the thyroid gland), eyes, ears, nasopharynx, lungs, heart, abdomen, liver, back, lymph nodes Table 6 | Days 0-7, day 21 | |
Secondary | Number of participants with abnormal changes in vital signs - Blood pressure (BP) | BP is measured in a sitting position after 10 minutes of rest | Days 0-7, day 21 | |
Secondary | Number of participants with abnormal changes in vital signs - Heart rate (HR) | HR is measured in a sitting position after 10 minutes of rest | Days 0-7, day 21 | |
Secondary | Number of participants with abnormal changes in vital signs - Respiratory rate (RR) | RR is measured in a sitting position after 10 minutes of rest | Days 0-7, day 21 | |
Secondary | Number of participants with abnormal changes in vital signs - Body temperature | Body temperature is measured in the armpit | Days 0, 1 (10 minutes before vaccination, 30 minutes and 2 and 5 hours after vaccination), days 2-7, day 21 | |
Secondary | Incidence and severity of systemic post-injection reactions | Day 1 (30 minutes, 3 and 5 hours after vaccination), days 2-21 | ||
Secondary | Incidence and severity of local post-injection reactions | Day 1 (30 minutes, 3 and 5 hours after vaccination), days 2-21 | ||
Secondary | Number of participants with abnormal changes data obtained from examinations by immunologist-allergist | Number of participants with clinically significant abnormalities | Days 1-7, day 21 | |
Secondary | Number of participants with abnormal changes of neurological examination data | Number of participants with clinically significant abnormalities | Days 0-7, day 21 | |
Secondary | Number of participants with abnormal changes data obtained from examinations by obstetrician-gynecologist | Examination: Respiratory organs, Blood circulation organs, Digestive organs, Organs of the urinary system, Mammary glands, Tone of the uterus, Fetal palpation results, Fetal auscultation results | Days 0-7, day 21 | |
Secondary | Number of participants with abnormal changes in the ultrasound data assessment of fetus and uterus | Days 0 (screening), 21 | ||
Secondary | Number of participants with clinically significant abnormalities - Complete blood count (CBC) | Red cells, Hemoglobin, ESR, White cells, Platelets, Relating to stab neutrophile, Segmented neutrophils, Lymphocytes, Eosinophils, Basophils, Monocytes | Days 0 (screening), 3, 21 | |
Secondary | Number of participants with clinically significant abnormalities - Biochemical blood test (BBT) | Creatinine, Urea, Aspartate aminotransferase (AST), Alanine transaminase (ALT), Lactate dehydrogenase (LDH), Total protein, C-reactive protein, Alkaline phosphatase, Bilirubin, Glucose, Cholesterol, Prothrombin complex, Thymol test, ß-lipoproteins | Days 0 (screening), 3, 21 | |
Secondary | Number of participants with clinically significant abnormalities - Urinalysis | Density, Leukocytes, pH, color, urine glucose, urine erythrocytes, bacteria | Days 0 (screening), 3, 21 | |
Secondary | Number of participants with abnormal changes of total IgE | Days 0 (screening), 3, 21 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03275389 -
A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years
|
Phase 1 | |
Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
Completed |
NCT05981846 -
A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19
|
Phase 2 | |
Completed |
NCT05044195 -
A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age
|
Phase 3 | |
Completed |
NCT02914275 -
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
|
Phase 3 | |
Completed |
NCT04590066 -
Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy
|
N/A | |
Recruiting |
NCT03778203 -
Development of Childhood Anti-influenza Immunity
|
Phase 4 | |
Completed |
NCT04527614 -
Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection
|
N/A | |
Terminated |
NCT03658629 -
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
|
Phase 2 | |
Completed |
NCT05269290 -
Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections
|
Phase 3 | |
Completed |
NCT06385821 -
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus
|
Phase 3 | |
Completed |
NCT02998996 -
Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02883972 -
Childhood Influenza Immunisation Invitation Trial in Schools
|
N/A | |
Completed |
NCT02984280 -
Specific Respiratory Infections as Triggers of Acute Medical Events
|
N/A | |
Completed |
NCT02867358 -
A Clinical Trial of KT07 Capsule in the U.S.A
|
Phase 2 | |
Completed |
NCT02545543 -
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age
|
Phase 3 | |
Completed |
NCT02621164 -
Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents
|
Phase 3 | |
Completed |
NCT02243774 -
Mail Outreach To Increase Vaccination Acceptance Through Engagement
|
N/A | |
Completed |
NCT02212106 -
A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years
|
Phase 4 | |
Completed |
NCT02344134 -
Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Adult and Elderly Subjects
|
Phase 3 |